ARGX / argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2022 Results - Earnings Call Transcript

November 1, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop more_horizontal

argenx SE (NASDAQ:ARGX ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corpor more_horizontal

October 24, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop more_horizontal

argenx exhibits robust financials with a Q2 YoY net sales surge to $269.3M and liquidity of $2.0B but faces increasing operating costs and R&D expendi more_horizontal

The stock gapped up nearly 28% on July 17, after announcing better-than-expected results from a clinical trial of its treatment for patients suffering more_horizontal

August 30 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of pe more_horizontal

Argenx has only two approved therapies, Vyvgart and Vyvgart Hytrulo. Vyvgart Hytrulo fared well in a trial to treat adults with chronic inflammatory d more_horizontal

July 20 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop more_horizontal